David H. Lum

3.6k total citations · 1 hit paper
25 papers, 1.7k citations indexed

About

David H. Lum is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, David H. Lum has authored 25 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 8 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in David H. Lum's work include Glycosylation and Glycoproteins Research (3 papers), Extracellular vesicles in disease (3 papers) and MicroRNA in disease regulation (3 papers). David H. Lum is often cited by papers focused on Glycosylation and Glycoproteins Research (3 papers), Extracellular vesicles in disease (3 papers) and MicroRNA in disease regulation (3 papers). David H. Lum collaborates with scholars based in United States, Germany and Canada. David H. Lum's co-authors include Alana L. Welm, Andrew M. Spence, Patricia E. Kuwabara, David Zarkower, Wei‐Qun Ding, Yvonne D. Trigoso, William C. Dooley, Bethany N. Hannafon, Yan D. Zhao and Zhizhuang Joe Zhao and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

David H. Lum

24 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasma exosome microRNAs are indicative of breast cancer

2016 474 citations Bethany N. Hannafon, Yvonne D. Trigoso et al. Breast Cancer Research profile →

Peers

Countries citing papers authored by David H. Lum

Since Specialization

Citations

This map shows the geographic impact of David H. Lum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Lum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Lum more than expected).

Fields of papers citing papers by David H. Lum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Lum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Lum. The network helps show where David H. Lum may publish in the future.

Co-authorship network of co-authors of David H. Lum

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Lum. A scholar is included among the top collaborators of David H. Lum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Lum. David H. Lum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Zinc-alpha-2-glycoprotein Secreted by Triple-Negative Breast Cancer Promotes Peritumoral Fibrosis 2024 ·Cancer Research Communications ·Surbhi Verma, (unknown), (unknown), (unknown), (unknown), (unknown), Aaron Atkinson, David A. Nix, David H. Lum, James E. Cox, Keren I. Hilgendorf	7
2	Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment 2024 ·Journal of Experimental & Clinical Cancer Research ·Eric A. Smith, R.L. Belote, Nelly M. Cruz, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Emilio Cortes-Sanchez, David H. Lum, John Hyngstrom, Hanlin Zeng, Dekker C. Deacon, Allie H. Grossmann, Richard M. White, Thomas A. Zangle, Robert L. Judson‐Torres	1
3	Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer 2023 ·Molecular Cancer Research ·Zannel Blanchard, (unknown), (unknown), Jeffery M. Vahrenkamp, Adriana C. Rodriguez, Elke A. Jarboe, (unknown), (unknown), Mark R. Flory, Hisham Mohammed, Katarzyna Modzelewska, David H. Lum, Jason Gertz	5
4	Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression 2023 ·Molecular Cancer Therapeutics ·(unknown), (unknown), David A. Kircher, William J. Burnett, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mona Foth, David H. Lum, Robert L. Judson‐Torres, (unknown), Matthew W. VanBrocklin, Martin McMahon, Sheri L. Holmen	4
5	Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line 2022 ·Scientific Reports ·(unknown), Zannel Blanchard, Jacob T. Polaski, (unknown), (unknown), Jeffery M. Vahrenkamp, Chieh‐Hsiang Yang, David H. Lum, Christy R. Hagan, Kimberly K. Leslie, Miles A. Pufall, Kristina W. Thiel, Jason Gertz	2
6	Aspirin Protects Melanocytes and Keratinocytes against UVB-Induced DNA Damage In Vivo 2020 ·Journal of Investigative Dermatology ·(unknown), Dileep Kumar, Tong Liu, (unknown), David H. Lum, Scott R. Florell, Christin E. Burd, Kenneth M. Boucher, Matthew W. VanBrocklin, Douglas Grossman	18
7	Development of a 89Zr radiolabeled anti-CD33 antibody for PET imaging of Acute Myeloid Leukemia 2020 ·(unknown), (unknown), Paul J. Shami, (unknown), David H. Lum, Jeffrey T. Yap	1
8	Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer 2019 ·Breast Cancer Research ·Sònia Palomeras, Ángel Díaz‐Lagares, Gemma Viñas, Fernando Setién, Humberto J. Ferreira, Glòria Oliveras, Ana B. Crujeiras, (unknown), David H. Lum, Alana L. Welm, Manel Esteller, Teresa Puig	50
9	Aspirin Suppresses PGE2 and Activates AMP Kinase to Inhibit Melanoma Cell Motility, Pigmentation, and Selective Tumor Growth In Vivo 2018 ·Cancer Prevention Research ·Dileep Kumar, (unknown), Ethika Tyagi, Tong Liu, (unknown), Ran Lu, David H. Lum, Sheri L. Holmen, J. Alan Maschek, James E. Cox, Matthew W. VanBrocklin, Douglas Grossman	40
10	A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis 2017 ·Nature Communications ·Qiyu Feng, Chengliang Zhang, David H. Lum, Joseph E. Druso, Bryant S. Blank, Kristin F. Wilson, Alana L. Welm, Marc A. Antonyak, Richard A. Cerione	212
11	Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer 2016 ·Clinical Cancer Research ·Ariadna Giró‐Perafita, Sònia Palomeras, David H. Lum, Adriana Blancafort, Gemma Viñas, Glòria Oliveras, (unknown), Ariadna Sarrats, Alana L. Welm, Teresa Puig	76
12	Plasma exosome microRNAs are indicative of breast cancer breakdown → 2016 ·Breast Cancer Research ·Bethany N. Hannafon, Yvonne D. Trigoso, (unknown), Yan D. Zhao, David H. Lum, Alana L. Welm, Zhizhuang Joe Zhao, Kenneth E. Blick, William C. Dooley, Wei‐Qun Ding	474
13	Vaccine-derived Mutation in Motif D of Poliovirus RNA-dependent RNA Polymerase Lowers Nucleotide Incorporation Fidelity 2013 ·Journal of Biological Chemistry ·(unknown), Xiaorong Yang, (unknown), Ibrahim M. Moustafa, Eric D. Smidansky, David H. Lum, Jamie J. Arnold, Craig E. Cameron, David D. Boehr	35
14	Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma 2012 ·Journal of Clinical Investigation ·Joanna J. Phillips, Emmanuelle Huillard, Aaron E. Robinson, (unknown), David H. Lum, Mei‐Yin C. Polley, Steven D. Rosen, David H. Rowitch, Zena Werb	76
15	Motif D of Viral RNA-Dependent RNA Polymerases Determines Efficiency and Fidelity of Nucleotide Addition 2012 ·Structure ·Xiaorong Yang, Eric D. Smidansky, Kenneth R. Maksimchuk, David H. Lum, (unknown), Jamie J. Arnold, Craig Cameron, David D. Boehr	73
16	Efficient Culturing and Genetic Manipulation of Human Pluripotent Stem Cells 2011 ·PLoS ONE ·Robert T. Schinzel, Tim Ahfeldt, Frank H. Lau, Youn‐Kyoung Lee, (unknown), Tony S. Shen, Derek Peters, David H. Lum, Chad A. Cowan	19
17	Gene Trap Disruption of the Mouse Heparan Sulfate 6- O -Endosulfatase Gene, Sulf2 2006 ·Molecular and Cellular Biology ·David H. Lum, Jenille Tan, Steven D. Rosen, Zena Werb	71
18	Sulf-2, a Proangiogenic Heparan Sulfate Endosulfatase, Is Upregulated in Breast Cancer 2005 ·Neoplasia ·Megumi Morimoto‐Tomita, Kenji Uchimura, Annette Bistrup, David H. Lum, Mikala Egeblad, Nancy Boudreau, Zena Werb, Steven D. Rosen	132
19	Direct protein–protein interaction between the intracellular domain of TRA-2 and the transcription factor TRA-1A modulates feminizing activity in C. elegans 2000 ·Genes & Development ·David H. Lum, Patricia E. Kuwabara, David Zarkower, Andrew M. Spence	324
20	Dominant Enhancers of Egfr in Drosophila melanogaster: Genetic Links Between the Notch and Egfr Signaling Pathways 1997 ·Genetics ·James V. Price, (unknown), David H. Lum, Ashton Breitkreutz	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact